Loading…
Kymera Therapeutics, Inc. is projected to rise to $146.15 by 2027, a +22% move from its current price of $119.35. KYMR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $115.32 | $119.36 | $123.54 | +0.01% |
| Jul 14 | $113.70 | $119.37 | $125.33 | +0.02% |
| Jul 15 | $112.47 | $119.38 | $126.72 | +0.03% |
| Jul 16 | $111.44 | $119.39 | $127.91 | +0.04% |
| Jul 17 | $110.55 | $119.40 | $128.96 | +0.04% |
| Jul 18 | $109.75 | $119.41 | $129.93 | +0.05% |
| Jul 19 | $109.02 | $119.42 | $130.82 | +0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $109.02 | $119.42 | $130.82 | +0.06% |
| Week 2 | $105.05 | $119.50 | $135.93 | +0.12% |
| Week 3 | $102.11 | $119.57 | $140.02 | +0.18% |
| Week 4 | $99.71 | $119.64 | $143.57 | +0.25% |
| Week 5 | $97.65 | $119.72 | $146.78 | +0.31% |
| Week 6 | $95.82 | $119.79 | $149.75 | +0.37% |
| Week 7 | $94.18 | $119.86 | $152.55 | +0.43% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
Its pipeline includes KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program in Phase II clinical trial for immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics, Inc. (KYMR) is currently trading at $119.24, with a market cap of $9.81B and a rank of 940.
The stock’s price today sits within a broader forecast horizon that envisions meaningful upside over time, with 2026 shown at an average price of $119.24 and higher averages projected for later years. The forecast table shows the 30-year trajectory moving to a $250.69 average by 2030 and continuing to rise to $1,542.02 on average by 2050, with a wide potential price path reflected in the max values. The annualized volatility is listed at 70%, underscoring substantial variability across the period.
Overall, the implied price path suggests upside potential across the forecast horizon, supported by a current price level and a sizable market capitalization.
A major floor 53.7% below — a decisive break under it would weaken the trend.
The nearest floor, 40.3% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 26.8% above — clearing it would confirm fresh momentum.
Key KYMR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KYMR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $117.30 | Buy | $117.18 | Buy |
| MA 10 | $114.63 | Buy | $113.53 | Buy |
| MA 20 | $104.14 | Buy | $106.01 | Buy |
| MA 50 | $89.87 | Buy | $95.05 | Buy |
| MA 100 | $87.28 | Buy | $87.94 | Buy |
| MA 200 | $78.11 | Buy | $78.21 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 70.79 | Sell |
| Stoch RSI (14) | 21.64 | Neutral |
| CCI (20) | 86.49 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 1.02 | Buy |
| ROC (12) | 21.48 | Buy |
| Bollinger %B (20,2) | 0.80 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 1.35 | Buy |
| Awesome (5,34) | 24.11 | Buy |
| Ultimate (7,14,28) | 67.56 | Neutral |
| Momentum (10) | 2.89 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 118.92 | Buy |
| ADX (14) | 35.91 | Buy |
| ATR (14) | 3.18 | Info |
The 30-day technical picture is bullish in sentiment, with RSI(14) at 80.
Key moving averages show a upside bias, with SMA50 at $87.93 and SMA200 at $77.10. The stock’s near-term support sits at $71.29 and resistance at $119.24. The 30-day trading range is $94.34 to $150.71.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $68.14 | $119.35 | $156.46 | 0% | Neutral | |
| $113.53 | $146.15 | $200.66 | +22% | Bullish | |
| $129.76 | $173.20 | $248.74 | +45% | Bullish | |
| $139.96 | $192.56 | $286.37 | +61% | Bullish | |
| $176.33 | $249.21 | $381.60 | +109% | Bullish | |
| $220.23 | $319.01 | $501.06 | +167% | Bullish | |
| $253.60 | $375.93 | $604.00 | +215% | Bullish | |
| $265.35 | $402.02 | $659.28 | +237% | Bullish | |
| $267.60 | $413.96 | $691.73 | +247% | Bullish | |
| $295.34 | $466.10 | $792.51 | +291% | Bullish | |
| $510.60 | $883.69 | $1,615.27 | +640% | Bullish | |
| $758.74 | $1,548.26 | $3,140.56 | +12.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $68.14 | $119.35 | $147.38 | +0.00% |
| August 2026 | $104.65 | $124.38 | $152.42 | +4.21% |
| September 2026 | $100.33 | $120.31 | $149.49 | -3.27% |
| October 2026 | $99.16 | $119.82 | $150.63 | -0.41% |
| November 2026 | $101.31 | $123.23 | $156.42 | +2.84% |
| December 2026 | $99.83 | $122.17 | $156.46 | -0.86% |
Click any year to see its month-by-month KYMR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect KYMR to range from $68.14 to $156.46 through 2026. The $119.35 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The KYMR price prediction for 2027 points to an average of $146.15 (low $113.53, high $200.66) — a potential gain of +22% on today's $119.35. Buyers look set to stay in control over this stretch.
In 2028, KYMR is projected to trade between $129.76 and $248.74, averaging $173.20 — a potential gain of +45% from today's $119.35. That is up +19% on the projected 2027 average. Momentum favours further upside here.
Kymera Therapeutics, Inc.'s 2029 outlook centres on $192.56, within a $139.96 to $286.37 range. That is up +11% on the projected 2028 average. That marks a +61% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, KYMR could reach as high as $381.60, with a base case around $249.21 and support toward $176.33 — roughly +109% from $119.35. Momentum favours further upside here.
Expect KYMR to range from $220.23 to $501.06 through 2031. The $319.01 average target implies a +167% move from current prices. That is up +28% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The KYMR price prediction for 2032 points to an average of $375.93 (low $253.60, high $604.00) — a potential gain of +215% on today's $119.35. Momentum favours further upside here.
In 2033, KYMR is projected to trade between $265.35 and $659.28, averaging $402.02 — a potential gain of +237% from today's $119.35. That is up +7% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Kymera Therapeutics, Inc.'s 2034 outlook centres on $413.96, within a $267.60 to $691.73 range. That is up +3% on the projected 2033 average. That marks a +247% change versus current levels. Momentum favours further upside here.
By 2035, KYMR could reach as high as $792.51, with a base case around $466.10 and support toward $295.34 — roughly +291% from $119.35. Buyers look set to stay in control over this stretch.
Expect KYMR to range from $510.60 to $1,615.27 through 2040. The $883.69 average target implies a +640% move from current prices. That is up +90% on the projected 2035 average. Momentum favours further upside here.
The KYMR price prediction for 2050 points to an average of $1,548.26 (low $758.74, high $3,140.56) — a potential gain of +12.0x on today's $119.35. Buyers look set to stay in control over this stretch.
Investing $1,000 in KYMR today (≈ 8.378718 KYMR) could be worth
$12,972.47
+$11,972.47 (+1197%) by 2050 · US Dollar
Based on the average projected KYMR price of $1,548.26 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KYMRwould be worth at today's price.
$1,000 invested in KYMR on Jul 10, 2025 (≈ 22.119001 KYMR) would be worth
$2,639.9
+$1,639.9 (+164.0%) today · 2.64× · US Dollar
Based on a KYMR entry price of $45.21 vs. today's $119.35.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $113.51 | $1,051.45 | +5.1% |
| 1 month ago | $78.23 | $1,525.63 | +52.6% |
| 3 months ago | $85.05 | $1,403.29 | +40.3% |
| 6 months ago | $73.09 | $1,632.92 | +63.3% |
| 1 year ago | $45.21 | $2,639.9 | +164.0% |
| All time (5.0y) ago | $48.74 | $2,448.71 | +144.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KYMR forecast.
Our base-case forecast reaches $240.00 around 2030.
Implied market cap at $240.00: $19.74B
The multi-year forecast highlights strong bullish momentum, with 2030 an average price of $250.69 and a return on investment of 110.2%. That year’s min is $176.05 and max is $386.92, underscoring substantial upside potential within a rising trend.
By 2040 the average moves to $889.90 with a 646.3% ROI, while the min is $505.89 and the max is $1,645.57. By 2050 the average is $1,542.02 with a 1,193.2% ROI, and the range extends from a min of $737.09 to a max of $3,170.40. The outlook across 2026–2050 is consistently bullish, but it remains an estimate and not a guarantee.
Risks and uncertainties should be considered, and these figures are not financial advice.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $250.69 with a 110.2% ROI. The forecast also lists a min of $176.05 and a max of $386.92 for that year.
The forecast depicts bullish sentiment for 2027 onward, with a 2030 average of $250.69, a 2040 average of $889.90, and a 2050 average of $1,542.02, along with substantial max-scenario upside. These are estimates, not guarantees, and do not constitute financial advice.
Yes. The 2040 max is $1,645.57 and the 2050 average is $1,542.02, both indicating values above $1,000 within the forecast horizon.
Current price: $119.24. Market cap: $9.81B.
The 30-day range is $94.34 to $150.71, with a bullish sentiment and an RSI(14) of 80. The SMA50 is $87.93 and the SMA200 is $77.10, with support at $71.29 and resistance at $119.24.
Kymera Therapeutics, Inc. Community Discussion
0Share your Kymera Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.